title: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
abstract: BACKGROUND
  Antithrombotic therapy with heparin plus aspirin reduces the rate of ischemic events in patients with unstable coronary artery disease. Low-molecular-weight heparin has a more predictable anticoagulant effect than standard unfractionated heparin, is easier to administer, and does not require monitoring.
  
  
  METHODS
  In a double-blind, placebo-controlled study, we randomly assigned 3171 patients with angina at rest or non-Q-wave myocardial infarction to receive either 1 mg of enoxaparin (low-molecular-weight heparin) per kilogram of body weight, administered subcutaneously twice daily, or continuous intravenous unfractionated heparin. Therapy was continued for a minimum of 48 hours to a maximum of 8 days, and we collected data on important coronary end points over a period of 30 days.
  
  
  RESULTS
  At 14 days the risk of death, myocardial infarction, or recurrent angina was significantly lower in the patients assigned to enoxaparin than in those assigned to unfractionated heparin (16.6 percent vs. 19.8 percent, P=0.019). At 30 days, the risk of this composite end point remained significantly lower in the enoxaparin group (19.8 percent vs. 23.3 percent, P=0.016). The need for revascularization procedures at 30 days was also significantly less frequent in the patients assigned to enoxaparin (27.1 percent vs. 32.2 percent, P=0.001). The 30-day incidence of major bleeding complications was 6.5 percent in the enoxaparin group and 7.0 percent in the unfractionated-heparin group, but the incidence of bleeding overall was significantly higher in the enoxaparin group (18.4 percent vs. 14.2 percent, P=0.001), primarily because of ecchymoses at injection sites.
  
  
  CONCLUSIONS
  Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase. This benefit of enoxaparin was achieved with an increase in minor but not in major bleeding.
authors.affiliation: Division of Cardiology, Allegheny University Hospitals-Hahnemann Division, Philadelphia, PA 19102, USA.
authors.forename: M
authors.initials: M
authors.lastname: Cohen
authors.forename: C
authors.initials: C
authors.lastname: Demers
authors.forename: E P
authors.initials: EP
authors.lastname: Gurfinkel
authors.forename: A G
authors.initials: AG
authors.lastname: Turpie
authors.forename: G J
authors.initials: GJ
authors.lastname: Fromell
authors.forename: S
authors.initials: S
authors.lastname: Goodman
authors.forename: A
authors.initials: A
authors.lastname: Langer
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: K A
authors.initials: KA
authors.lastname: Fox
authors.forename: J
authors.initials: J
authors.lastname: Premmereur
authors.forename: F
authors.initials: F
authors.lastname: Bigonzi
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000401:mortality; D001241:Aspirin / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D012306:Risk
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006493:Heparin; D001241:Aspirin